Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681915 | 1.00 | MAPT (0.46) | MAPTALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL31105824 | 0.89 | MAPT (0.45) | MAPTALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL26617522 | 0.85 | MAPT (0.47) | MAPTALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL26617641 | 0.85 | SCN10A (0.43) | MAPTALDH1A1MAOBSCN10A | |
| SCHEMBL30681940 | 0.85 | SCN10A (0.43) | MAPTALDH1A1MAOBSCN10A | |
| SCHEMBL26730778 | 0.84 | MAPT (0.45) | MAPTALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL31561373 | 0.83 | MAPT (0.45) | MAPTKDM4ETSHRSMN1; SMN2TP53 | |
| SCHEMBL31105747 | 0.81 | ALDH1A1 (0.41) | MAPTALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL26617769 | 0.81 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL26617995 | 0.80 | MAOB (0.45) | KDM4EMAPK1MAOBMGLLSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4455130-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | SCN8A, SCN10A, SCN7A | MAPT 1605/4885ALDH1A1 3194/4885KDM4E 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.